



## World Federation of Neurology Needs Registry Survey

In partnership with its member societies, the World Federation of Neurology is asking neurologists around the world to complete this survey so that the WFN can compile an inventory of the most important deficiencies causing inequalities in the prevention and care of neurological disorders.

Hundreds of millions of people worldwide are affected by neurological disorders, and millions of them are disabled or die each year. The disease burden of neurological disorders, particularly in low to middle-income countries, is expected to grow exponentially in the next decade. Despite this, major barriers such as lack of therapeutics, facilities, specialist nurses and neurologists continue to negatively affect the quality of neurological care.

The WFN registry of needs will provide an essential real-world view that will assist the WFN in identifying disparities in the delivery and quality of neurological care and inform decisions prioritising and targeting future remedying efforts.

This survey has fourteen questions and will take about ten minutes to complete. Please answer to the best of your ability and feel free to consult with colleagues if you do not know the answers to any of the questions. Questions with asterisks (\*) must be answered. Please contact us at [kimberly@wfneurology.org](mailto:kimberly@wfneurology.org) if you have any questions before, during or after completing the survey.

Thank you very much for your time and valuable contribution to fostering quality neurology and brain health worldwide!

---

### \* 1. Specifics

Name	<input type="text"/>
WFN Member Society	<input type="text"/>
Number of years as a practicing neurologist	<input type="text"/>
Email address	<input type="text"/>
Contact number (optional)	<input type="text"/>

2. What position, if any, have you held or currently hold in the WFN Member society?

3. In which institution(s) did you receive most of your neurological training?

\* 4. In which country do you practice neurology?

Please note that the next questions all apply to the country where you practice neurology

\* 5. Approximate total number of practising neurologists in your country

6. What best describes the main healthcare system(s) in your country?

Universal healthcare - government/insurance funded

Mixed private/public

Limited access to public/free healthcare

Comments

7. Which types of centres or departments provide neurological care?

Academic/University based

Hospital based

Speciality Clinics/Centres

Private office settings

Other (please specify)

8. Neurological nurse training programme duration

Less than a year

One year or more

No neurological nurse training programme available

Comments

9. Approximate total number of imaging machines available that can be used for neurology. (Please include those dedicated to neurology and those in other departments available for neurological use).

MRI scanners

CT scanners

MRI/CT scanners available for acute neurology (stroke)

Comments

\* 10. Which of the following neurological speciality services are accessible and affordable for at least 70% of the people in the country where you practice neurology?

Note: Please tick both boxes for Accessible and Affordable if that is the case. Boxes left unticked will count as (either) inaccessible or unaffordable.

	Accessible to >70%	Affordable to >70%	Neither affordable nor accessible
Electroencephalography (EEG)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Neurophysiology (EMG, evoked potentials)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Stroke Unit	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Alzheimer's/major neurocognitive disorder	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Epileptology	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Headache Disorders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Movement Disorders/Parkinson's	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Neurorehabilitation	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Neuroinfections	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Neurodevelopmental Disorders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Neuropsychology	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Neuropaediatrics	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Neurogenetics	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Neuromuscular Disorders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Comments

**\* 11. Which of the medicines below are readily available, affordable and accessible for neurological use in your country?**

	Available	Accessible to >70%	Affordable to >70%	Not available, accessible or affordable
Dopaminergics: Levodopa based (eg Madopar, Sinemet etc)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Dopamine agonists (eg pramipexole etc)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Antiepileptics: 1st generation (eg phenobarbitone, phenytoin, carbamazepine, valproate etc)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Antiepileptics: 2nd generation ( eg lamotrigine, levetiracetam etc)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Benzodiazepines ( eg clonazepam etc)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Antiplatelets (eg aspirin, clopidogrel etc)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anticoagulants (eg warfarin, NOACS; rivaroxaban etc )	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Multiple Sclerosis disease modifying therapies ( eg interferon beta, fingolimod etc)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Anticholinesterase (AChE) inhibitors ( eg pyridostigmine)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Beta-blockers (eg propranolol etc)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Thiazide diuretics (eg hydrochlorothiazide etc)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
ACE Inhibitors (eg enalapril, ramipril etc)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Calcium channel blockers (eg amlodipine etc)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Comments

**12. What are some of the challenges facing a neurologist in your country?**

- Costs of neurological care to patients
- Therapeutics availability
- Insufficient diagnostics
- Neurology specialist training availability
- Neurology subspecialty training availability
- Lack of specialised centres ( eg stroke, epilepsy)
- Lack of primary healthcare workers to diagnose, treat, refer
- Limited access to neurological care
- Social stigma, misinformation, traditional beliefs
- Attitudes, compliance and/or adherence
- Non-inclusion of neurological disorders in health system
- Limited institutional or community care
- Lack of attention to neurological noncommunicable diseases
- None of the above

Comments

**\* 13. Please comment on the three most urgent needs in regards to neurology in your country ( not restricted to the list above)**

- 1)
- 2)
- 3)

**14. We sincerely appreciate your valuable assistance with this survey! Please add any comments you may have in the box below and when finished click the "DONE" tab**